Gynecologic Cancers

International researchers from seven countries conducted a prospective study to determine risk reduction of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy and examine other factors, such as impact of this procedure on mortality and five year survival.

The genomic instability inherent in serous ovarian cancer poses treatment challenges, but it also represents a target that can be exploited through the use of PARP inhibitors

The "renaissance in immunology" is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand

Sharon Tollin, PhD, ARNP-BC, OCN®, discusses the unmet need for information regarding patients who have undergone prophylactic risk-reducing surgery (such as mastectomy and removal of tubes and ovaries).

Oncology nurses can lead the way in efforts to protect the next generation from this type of cancer if they know the facts about HPV vaccination for both girls and boys

Lauren McCaulley, BSN, RN, OCN, University Hospitals Seidman Cancer Center, Cleveland, Ohio, describes ovarian cancer education at her institution.

Cancer centers are beginning to establish oncology nurse navigator programs with integrated processes for assessment, identification, referral, education, care, and support for patients whose gynecologic cancers may be genetically-based.

The decision about whether to get tested for a genetic mutation that may predispose a person to certain cancers is a difficult one for many patients to make. Even more difficult for mutation carriers is deciding whether to undergo a prophylactic surgical procedure.

Due to the high lifetime risk of ovarian cancer and the poor ovarian cancer surveillance options available, women who carry BRCA1 or BRCA2 mutations are advised to remove their ovaries and fallopian tubes by age 40 or when childbearing is complete.

L. Stewart Massad, MD, discusses recent updates to guidelines for cervical cancer screening intended to implement prevention strategies that are less intrusive and reduce morbidity.

A pair of studies could change the way patients are evaluated for mutations of BRCA1 and BRCA2, two cancer susceptibility genes closely associated with breast and ovarian cancers, as well as other tumor types.

Cristi Radford, MS, CGC, from the Sarasota Memorial Hospital, discusses examining cancer gene panels using next generation sequencing for patients with ovarian cancer.

Michael L. Krychman, MD, Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine, discusses managing and treating sexual health concerns in cancer patients and survivors.

For Tiffany Keller-Fritz, the safety of her unborn child, weighed against the urgent need to initiate treatment, required close collaboration between her oncologists and OB-GYN.

Heidi Donovan from the University of Pittsburgh School of Nursing Discusses Prioritizing Symptoms

A chronic shortage of the most commonly used taxane for ovarian cancer would add almost $9 million a month to the cost of care if half of newly diagnosed cases were affected.

Whether surgically or medically induced, early menopause forces women to deal with a host of emotional, physical, and practical issues.

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

New findings demonstrate a recent increase in the annual completion rates of vaccination against human papillomavirus (HPV) infection.

Dr. Teresa Woodruff from Feinberg School of Medicine, Northwestern University, Discusses Oncofertility Insurance Coverage

Women are now advised to have fewer screenings over their lifetime.

Now more than ever, oncology nurses need to be able to fill the knowledge gap and accurately educate their patients and the public about cancer screening tests and their frequency.

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Oncology Nurse Fiona McCaughan on Struggles Facing Intraperitoneal Ovarian Cancer Treatments

Contrary to the traditionally slow pace of research adoption, the American College of Surgeons Oncology Group's Z0011 trial has seemingly changed practice overnight

A breast cancer diagnosis is a highly distressing, life-changing experience

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.